Product Description
Mechanisms of Action: GSTA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MabVax Holdings
Company Location: SAN DIEGO CA 92121
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Preleukemia|Neutropenia|Myelodysplastic Syndrome|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TLK199.2103 | P2 |
Terminated |
Neutropenia |
2013-05-01 |
|
TLK199.2107 | P2 |
Terminated |
Myelodysplastic Syndrome|Preleukemia |
2013-02-01 |
|
TLK199.2108 | P2 |
Terminated |
Myelodysplastic Syndrome|Preleukemia |
2013-02-01 |
|
TLK199.2101 | P2 |
Completed |
Preleukemia|Myelodysplastic Syndrome |
2011-07-01 |